Challenges of Immunogenicity Assessment Course, Nov. 16, 2015, Baltimore, MD

•

1 like•179 views

When: November 16, 2015 (5:30-8:30 pm) Where: Hilton Baltimore, Baltimore, MD Instructors: Jim McNally, Ph.D., Associate Director, PDM Immunogenicity Expert, EMD Serono Amy Loercher, Ph.D., Manager, Clinical Immunology, GlaxoSmithKline This interactive session of intermediate level will focus on the potential challenges of immunogenicity testing in preclinical and clinical development and present case studies demonstrating how they can be handled. Attendees are encouraged to contribute with their own experiences and to bring questions for discussion or submit to the meeting organizers in advance. The following topics will be covered: * Challenges and approaches to resolve commonly encountered issues * Multi-domain binding proteins * Pre-existing ADAs * Emerging trends in the development of neutralizing antibody assays * Cross-reactivity to endogenous proteins * Clinical implications of ADAs This short course will be held at CHI's Seventh Annual Immunogenicity and Bioassay Summit 2015.

Healthcare

DINNER SHORT COURSE
ANNOUNCEMENT
The following topics will be covered:
• Challenges and approaches to resolve commonly
encountered issues
• Multi-domain binding proteins
• Pre-existing ADAs
• Emerging trends in the development of neutralizing
antibody assays
• Cross-reactivity to endogenous proteins
• Clinical implications of ADAs
CHALLENGES OF
IMMUNOGENICITY ASSESSMENT
November 16, 2015 • 5:30-8:30 p.m. • Hilton Baltimore • Baltimore, MD
Instructors:
Jim McNally, Ph.D.,
Associate Director, PDM Immunogenicity
Expert, EMD Serono
Amy Loercher, Ph.D.,
Manager, Clinical Immunology, GlaxoSmithKline
This interactive session of intermediate level will focus on the potential challenges
of immunogenicity testing in preclinical and clinical development and present case
studies demonstrating how they can be handled. Attendees are encouraged to
contribute with their own experiences and to bring questions for discussion or
submit to the meeting organizers in advance.
NOVEMBER 17-19, 2015
HILTON BALTIMORE
BALTIMORE, MD
This short course is being held at
How to Register: ImmunogenicitySummit.com or call 781-972-5400
Make Plans to Attend the Number 1 Immunogenicity and Bioassay Event in the U.S.
BringingTogether Industry, Academia and Regulatory Authorities. Join over 250 ofYour Peers!

More from James Prudhomme

CHI's Immunogenicity & Bioassay Summit 2018

James Prudhomme

Next Generation Dx Summit has grown to more than 1,000 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its tenth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.

CHI's 10th Annual Next Generation Dx Summit, August 20-24, 2018, Washington, DC

James Prudhomme

Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.

CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DC

James Prudhomme

The Immuno-Oncology one-day course provides an overview of the rapidly evolving subject of immune-oncology. Delegates are offered a thorough understanding of the basics of tumor immunology as well as the essentials of immunotherapy and its application in cancer medicine. Examples of both how biologics work in the practice of oncology and of the challenges presented are demonstrated. The program has been developed specifically to support the needs of the pharmaceutical, biotechnology and medical technology industry personnel. It is ideal for individuals with little understanding of the immunotherapy of cancer and those with an existing basic knowledge. Detailed presentations and discussion with Healthcare’s experienced and knowledgeable faculty enable thorough insight to this important subject area.

Immuno-Oncology Course, organized by Healthcare Education Services

James Prudhomme

Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed. Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.

Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...

James Prudhomme

This course reviews the hematological system and provides an overview on the spectrum of hematologic cancers. The expert teaching team, comprising currently practising physicians, guides course attendees through the pathophysiology of Hematologic Cancers - An Introduction such as leukemias, lymphomas and myeloma. Common treatments and management of these malignancies are discussed as well as the challenges these treatments present to patients. The issues and complications of bone marrow and stem cell transplant are also reviewed. Case studies and open discussion form an integral part of the program.

Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...

James Prudhomme

Cambridge Healthtech Institute offers two back-to-back symposia on the operational aspects of precision medicine trials and the improvement of infrastructure to better support those trials. The 2nd Annual Managing Precision Medicine Trials Symposium (January 24-25, 2017) focuses on strategizing design for biomarker driven trials and novel clinical trial design. The Inaugural Sample, Lab and Diagnostics Services in Clinical Trials Symposium (January 25-26, 2017) focuses on clinical sample management and sourcing and diagnostics services.

Overcome Operational Challenges in Biomarker-driven Clinical Trials

James Prudhomme

Cambridge Healthtech Institute (CHI) is pleased to announce the Third Annual FAST: Functional Analysis and Screening Technologies Congress. Now in its third year, the FAST Congress brings you the latest technologies and research in cellular screening. The Third Annual Phenotypic Drug Discovery meeting will return with new updates and case studies in phenotypic screening, high-content analysis, physiologically-relevant cellular models, chemical genomics and chemical proteomics. The rapidly evolving area of 3D cellular models will be addressed by two back-to-back meetings, with the Inaugural 3D Cell Culture: Organoid, Spheroid, and Organ-on-a-Chip Models meeting focusing on the new predictive cellular models for drug discovery and toxicity assessment. It will review the use of primary and stem cells, complex co-culture cell models, tumor spheroid models, novel organ-on-a-chip models for efficacy and safety screening, functional analysis, and compound profiling. The Third Annual Screening and Functional Analysis of 3D Models meeting will follow with case studies of phenotypic and high-content screening of complex 3D cellular systems for compound and target selection. The 2014 Congress attracted more than 250 senior delegates, representing over 160 companies from 20 countries. With half of the attendees from big pharma and biotech and a third from academia and government, the FAST Congress offers exclusive networking opportunities with diverse international attendance. Please join our focused Screening event and learn from 60+ scientific presentations, an assortment of educational courses, 20+ exhibitors and your fellow expert delegates. We look forward to seeing you at the event.

CHI's FAST: Functional Analysis & Screening Technologies Congress, Nov. 9-11,...

James Prudhomme

CHI's Immunogenicity and Bioassay Summit 2015

James Prudhomme

The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.

Next Generation Dx Summit 2015 - Moving Assays to the Clinic

James Prudhomme

Cambridge Healthtech Institute's fourth annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. This four-day summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Themes throughout will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness.

CHI's Clinical Trial Oversight Summit, June 1-3, 2015, Boston, MA

James Prudhomme

Call for Posters: Functional Analysis & Screening Technologies

James Prudhomme

Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.

Functional Analysis & Screening Technologies Congress

James Prudhomme

Cambridge Healthtech Institute (CHI) will once again offer comprehensive training at the Sixth Annual Immunogenicity and Bioassay Summit 2014. The following courses are led by well-respected professionals in the pharmaceutical industry who have much experience in helping investigators overcome their difficulties with these challenging assays and with risk assessment. Delegates will enjoy an intimate setting with their peers and instructors and have the opportunity to ask questions and exchange experiences.

Short Courses at CHI's Immunogenicity and Bioassay Summit 2014

James Prudhomme

Immunogenicity and Bioassay Summit 2014

James Prudhomme

Course: Development of High-Dose Biologics Dosage Forms

James Prudhomme

When: May 4, 2014 Where: Seaport World Trade Center, Boston, MA Proteins and peptides represent a significant segment of the therapeutics spectrum with many promising candidates under early development or in late-stage clinical trials. Several of these molecules are poised to make a substantial impact, especially in the under-represented or unrepresented categories such as neurological disorders and neurodegenerative diseases. A key challenge to be overcome with protein and peptide based biologics, however, is their effective delivery to the target site while achieving the optimum balance of stability, safety, bioavailability, and patient compliance. This short course will provide a broad overview of the opportunities and challenges in the development of the next generation of protein and peptide therapeutic delivery systems.

Course: Challenges and Opportunities in Protein and Peptide Drug Delivery

James Prudhomme

The Safety Stream at PEGS will guide attendees through the process of developing a comprehensive immunogenicity and PK/PD strategy to ensure successful biologics. With a focus on novel constructs, high level science and expert advice will examine assay strategies, management of product immunogenicity, and modeling PK/PD to improve drug performance. Risk assessment and regulatory guidance to ensure clinical success and a competitive advantage will also be addressed.

PK/PD and Immunogenicity Conferences, May 2014, Boston, MA - part of PEGS

James Prudhomme

PEGS - the essential protein & antibody engineering summit

James Prudhomme

Structure-Based Drug Design Facts & Figures Infographic

James Prudhomme

More from James Prudhomme (20)

CHI's Immunogenicity & Bioassay Summit 2018

CHI's 10th Annual Next Generation Dx Summit, August 20-24, 2018, Washington, DC

CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DC

Immuno-Oncology Course, organized by Healthcare Education Services

Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...

Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...

Overcome Operational Challenges in Biomarker-driven Clinical Trials

CHI's FAST: Functional Analysis & Screening Technologies Congress, Nov. 9-11,...

CHI's Immunogenicity and Bioassay Summit 2015

Next Generation Dx Summit 2015 - Moving Assays to the Clinic

CHI's Clinical Trial Oversight Summit, June 1-3, 2015, Boston, MA

Call for Posters: Functional Analysis & Screening Technologies

Functional Analysis & Screening Technologies Congress

Short Courses at CHI's Immunogenicity and Bioassay Summit 2014

Immunogenicity and Bioassay Summit 2014

Course: Development of High-Dose Biologics Dosage Forms

Course: Challenges and Opportunities in Protein and Peptide Drug Delivery

PK/PD and Immunogenicity Conferences, May 2014, Boston, MA - part of PEGS

PEGS - the essential protein & antibody engineering summit

Structure-Based Drug Design Facts & Figures Infographic

Recently uploaded

Abortion pills in Abu Dhabi ௵+918133066128௹Un_wandted Pregnancy Kit in Dubai UAE

Abortion pills in Kuwait Cytotec pills in Kuwait

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

mcsprintern12024

Leading large scale change: a life at the interface between theory and practice

HelenBevan4

Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf

Dr. Afreen Nasir

Leadership Style - Code and Rapid Response Workshop

Brian Locke

Top 20 sexiest Indian pornstars list rated by popularity and hotness. Best Indian pornstar are Sunny Leone, Anjali Kara, Shazia Sahari. Browse the list of the hottest indian pornstars at pornpics.de. ❤️Here you can find FREE porn pics of the best female pornstars from India. INDIAN TOP PORNSTAR – #1 ANJALI KARA. Anjali Kara Indian Porn Star. The name Anjali Kara comes to mind when talking the top Indian female porn star name. CheckOut My website : https://www.niamh.in/indian-pornstars.html If you are a fan of Indian Porn Star then you will get here lots of Hot photos of Indian Porn Star. One of the top best Hot Indian Porn Star Name. You know that peoples are crazy about watching the videos of Indian Porn Stars. And here you will find the best porn star name to have fun with. Top Indian Pornstars We have to tell you about all the porn star models ( https://www.niamh.in ) who have made Indian XXX videos so far. Because in today’s time, many women and girls of our age have started having sex a lot. If you look, the list of all Indian porn star is given below for you. Here it will also be told which porn star’s hot sex video is uploaded on which website. How many more videos have been made? All kinds of information about all Indian sex girls will also be provided to you. Many of you have had to go through this. All are Hot Indian porn star girls. Which one is there and a new desi girl porn star’s video has come. Or we have to find out his name and information. Or there are many people like this in our India. Who like to watch sex videos as per their choice. बॉलीवुड एक्ट्रेस सनी लियोनी को हम एक ऐसी पोर्न स्टार के तौर पर जानते हैं जो भारतीय मूल की हैं.

Top 20 Famous Indian Female Pornstars Name List 2024

minkseocompany

100%Safe& effective {+918133066128} Abortion Pills for sale Kuwait all areas @

Abortion pills in Kuwait Cytotec pills in Kuwait

The connection between genetics and kidney disease lies in the role of inherited genetic factors that can increase the risk of developing various kidney diseases. Certain kidney diseases, such as Polycystic Kidney Disease (PKD) and Alport Syndrome, have a clear genetic component where mutations in specific genes contribute to the development of these conditions. Understanding these genetic basis is vital for assessing the risk of kidney disease in individuals with family history and for advancing personalized medicine approaches in prevention, diagnosis and treatment. Genetic testing plays a significant role in identifying these predispositions and guiding healthcare strategies.

GENETICS and KIDNEY DISEASES /

AFFIFA HUSSAIN

Session-10-Infants-with-Special-meeds.ppt

Medidas Medical Center INC

An overview of Muir Wood Adolescent and Family Services teen treatment progra...

pdamico1

LTM Session-8-Practices-that-assist-BF..ppt

Medidas Medical Center INC

A month-long celebration of the POSHAN Abhiyan mission places special attention on Severe Acute Malnourished (SAM) children. It is an umbrella scheme covering the Integrated Child Development Services (ICDS) (Anganwadi Services, Poshan Abhiyan, Scheme For Adolescent Girls, National Creche Scheme). Poshan 2.0 will include three significant initiatives within its purview: Anganwadi Services, the Scheme for Adolescent Girls, and Poshan Abhiyaan. Moreover, Poshan 2.0 will concentrate on Maternal Nutrition, Infant and Young Child Feeding Norms, Treatment of MAM/SAM, and Wellness through AYUSH.

POSHAN ABHIYAAN-Poshan 2.0 will concentrate on Maternal Nutrition, Infant and...

sheeza38

Organisation and Management of Eye Care Programme Service Delivery Models

Harsh Rastogi

Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt

Medidas Medical Center INC

Disinfection of medical instruments is important for preventing the spread of disease. Cleaning and disinfecting reusable equipment after it comes into contact with patients can be expensive, both in the cost of the disinfection procedure, but also in terms of time away from the patients themselves. Not all medical instruments can be fully sterilized after each use. Thankfully, not all reusable instruments need the highest level of disinfection. But how to determine the minimum level of disinfection in a given situation? Earle H. Spaulding devised a rational approach to disinfection and sterilization of patient-care items and equipment Spaulding believed the nature of disinfection could be understood readily if instruments and items for patient care were categorized as critical, semi-critical, and non-critical according to the degree of risk for infection involved in use of the items. Spaulding recognized that the need for disinfection of equipment in medical settings ranged from non-critical to semi-critical to critical, depending on the likelihood of spreading disease. For example, sterilization is necessary for equipment that comes into contact with a patient’s bloodstream or sterile tissue. This category of equipment, such as surgical knives, is designated “critical” because it presents a high risk of disease transmission from patient to patient. Equipment that only touches healthy, unbroken skin presents a low risk of contamination because intact skin acts as an effective barrier to most microorganisms. Examples in this “non-critical” category include bedpans, blood-pressure cuffs, and bedrails. In between those two scenarios, a “semi-critical” level of disinfection presents a medium risk of contamination. This would include equipment such as endoscopes used on mucous membranes or areas of broken skin.

Spauldings classification ppt by Dr C P PRINCE

DR.PRINCE C P

A well-known hospital in Gwalior, Madhya Pradesh, ITM Hospital & Research Center has recently updated its super specialty and elevated the pre-existing facilities including critical care and minimal invasive surgery protocols. As per the hospital's management team, "The 300-bedded tertiary care hospital operates under the guidance of highly experienced medical and healthcare professionals and includes 20 ICU beds, 20 beds for Obs, Gynae, and NICU, three modern operating theaters, a well- equipped and 24x7 available ER department, dialysis center, a dedicated mother and child care unit, along with highly advanced technologies like CT scan, MRI, Bone DEXA along with ECHO, TMT, Physiotherapy and more. Our highly experienced doctors bring a multidisciplinary approach across 25+ super specialties, including oncology, cardiology, joint replacement, minimal access surgery and others. We aim to enhance health care in Gwalior, Madhya Pradesh by providing quality medical care with trust, transparency and empathy while meeting all safety standards," says Mr. Ramashankar Singh, Chairman of the hospital. The hospital has also been recognised as the best emerging hospital in the vicinity for several specialties for following the moral of “Sewa Samta aur Sammaan”. Dr. Ramashankar adds, "This recognition is a testament to our mission of serving people with the best critical care and minimal invasive surgery. We remain committed to delivering outcome-driven experiences and care to treat and heal people, based on the same values that the group has followed for the past three decades”

ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...

jvomprakash

Famous Indian Vedic Astrologer | Best Astrological Solutions UK

darmandersingh4580

Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.

mHealth Israel_Healthcare Finance and M&A- What Comes Next

Levi Shapiro

Lactation Mraining Management Session-2-Comm-Building-Conf.ppt

Medidas Medical Center INC

WORLD HEALTH ORGANIZATION WE CHAMPION HEALTH AND A BETTER FUTURE FOR ALL’ INTRODUCTION- WHO leads and champions global efforts to give everyone, everywhere, an equal chance to live a healthy life. HISTORY- founded in 1948, 7 April HEADQUARTERS- Geneva OFFICES- 6 semi autonomus regional and 150 fields offices DIRECTOR- Dr. Tedros Adhanam Ghebeyesus OBJECTIVES- Direction, co-ordination agencies Collaboration with local bodies Help the government in health services Proper technological assistance To attain highest possible level of health Prioritize and support health Formulate health policies Disease inspection and analysis Health education GOAL: To ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies and provide a further billion people with better health and well being ORGANIZATION: executive board, secretariat, world health assembly FUNCTION: FOR UNIVERSAL HEALTH Focus on PHCare Sustainable financing and protection Access to health products and medicines Training of health workforce and advice on labor policies Support people participation in National health policies Increasing monitoring, data and information FOR HEALTH EMERGENCIES Identification, mitigation and risk management Prevention and support of development of tools Detect and respond to acute health emergencies Support delivery of essential health services FOR HEALTH AND WELL BEING Address social determinants Promote intersectoral approach for health Prioritize health in all policies and healthy settings THROUGH WORK, ADDRESS Prevention of non- communicable disease Mental health promotion Climate change Antimicrobial resistance Elimination and eradication of communicable disease UNITED NATION FUND FOR POPULATION ACTIVITYINTRODUCTION- SEXUAL AND REPRODUCTIVE HEALTH AGENCY MISSION- To deliver a world where every pregnancy is wanted, every childbirth is safe, and every young person’s potential is fullfilled AIM- to improve reproductive and maternal health worldwide ESTABLISHED YEAR- 1969 (1974 in INDIA) HEADQUARTER- NEW YORK DIRECTOR- Dr. Natalia Kanem (2017) FUNCTION Develop national healthcare Increasing the access to birthcontrol Leading campaigns against child marriage Prevention of violence against gender Prevention of female genital mutiliation Treatment and prevention of STD and RTI MCH care HIV prevention and treatment IEC on sexuality and treatment of infertility and Abortion FOCUS area: Reproductive health Gender equality Population and development strategies Girl education Political participation for women FGM Child marriage UNITED NATION DEVELOPMENT PROGRAMME 1965 ESTABLISHED- 22 November. 1965 HEADQUARTER- New York HEAD- Achim steiner STRUCTURE- 170 member countries and territories INTRODUCTION- Advocates for change and connect countries to knowledge, experience and resources to help people bulid a better life for themselves Encourages Human right protection, women empowerment in all its programme

INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx

AnushriSrivastav

Recently uploaded (20)

Abortion pills in Abu Dhabi ௵+918133066128௹Un_wandted Pregnancy Kit in Dubai UAE

aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Leading large scale change: a life at the interface between theory and practice

Tortora PRINCIPLES OF ANATOMY AND PHYSIOLOGY - Tortora - 14th Ed.pdf

Leadership Style - Code and Rapid Response Workshop

Top 20 Famous Indian Female Pornstars Name List 2024

100%Safe& effective {+918133066128} Abortion Pills for sale Kuwait all areas @

GENETICS and KIDNEY DISEASES /

Session-10-Infants-with-Special-meeds.ppt

An overview of Muir Wood Adolescent and Family Services teen treatment progra...

LTM Session-8-Practices-that-assist-BF..ppt

POSHAN ABHIYAAN-Poshan 2.0 will concentrate on Maternal Nutrition, Infant and...

Organisation and Management of Eye Care Programme Service Delivery Models

Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt

Spauldings classification ppt by Dr C P PRINCE

ITM HOSPITAL The hospital has also been recognised as the best emerging hosp...

Famous Indian Vedic Astrologer | Best Astrological Solutions UK

mHealth Israel_Healthcare Finance and M&A- What Comes Next

Lactation Mraining Management Session-2-Comm-Building-Conf.ppt

INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx

Challenges of Immunogenicity Assessment Course, Nov. 16, 2015, Baltimore, MD

1. DINNER SHORT COURSE ANNOUNCEMENT The following topics will be covered: • Challenges and approaches to resolve commonly encountered issues • Multi-domain binding proteins • Pre-existing ADAs • Emerging trends in the development of neutralizing antibody assays • Cross-reactivity to endogenous proteins • Clinical implications of ADAs CHALLENGES OF IMMUNOGENICITY ASSESSMENT November 16, 2015 • 5:30-8:30 p.m. • Hilton Baltimore • Baltimore, MD Instructors: Jim McNally, Ph.D., Associate Director, PDM Immunogenicity Expert, EMD Serono Amy Loercher, Ph.D., Manager, Clinical Immunology, GlaxoSmithKline This interactive session of intermediate level will focus on the potential challenges of immunogenicity testing in preclinical and clinical development and present case studies demonstrating how they can be handled. Attendees are encouraged to contribute with their own experiences and to bring questions for discussion or submit to the meeting organizers in advance. NOVEMBER 17-19, 2015 HILTON BALTIMORE BALTIMORE, MD This short course is being held at How to Register: ImmunogenicitySummit.com or call 781-972-5400 Make Plans to Attend the Number 1 Immunogenicity and Bioassay Event in the U.S. BringingTogether Industry, Academia and Regulatory Authorities. Join over 250 ofYour Peers!

Challenges of Immunogenicity Assessment Course, Nov. 16, 2015, Baltimore, MD

Recommended

Recommended

More Related Content

More from James Prudhomme

More from James Prudhomme (20)

Recently uploaded

Recently uploaded (20)

Challenges of Immunogenicity Assessment Course, Nov. 16, 2015, Baltimore, MD